Abstract
Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 593-603 |
| Number of pages | 11 |
| Journal | Journal of Child and Adolescent Psychopharmacology |
| Volume | 17 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 1 2007 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Psychiatry and Mental health
- Pediatrics, Perinatology, and Child Health
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). / Vitiello, Benedetto; Abikoff, Howard B.; Chuang, Shirley Z.; Kollins, Scott H.; McCracken, James T.; Riddle, Mark A; Swanson, James M.; Wigal, Tim; McGough, James J.; Ghuman, Jaswinder K.; Wigal, Sharon B.; Skrobala, Anne M.; Davies, Mark; Posner, Kelly; Cunningham, Charles; Greenhill, Laurence L.
In: Journal of Child and Adolescent Psychopharmacology, Vol. 17, No. 5, 01.11.2007, p. 593-603.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)
AU - Vitiello, Benedetto
AU - Abikoff, Howard B.
AU - Chuang, Shirley Z.
AU - Kollins, Scott H.
AU - McCracken, James T.
AU - Riddle, Mark A
AU - Swanson, James M.
AU - Wigal, Tim
AU - McGough, James J.
AU - Ghuman, Jaswinder K.
AU - Wigal, Sharon B.
AU - Skrobala, Anne M.
AU - Davies, Mark
AU - Posner, Kelly
AU - Cunningham, Charles
AU - Greenhill, Laurence L.
PY - 2007/11/1
Y1 - 2007/11/1
N2 - Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.
AB - Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p <0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.
UR - http://www.scopus.com/inward/record.url?scp=35848947225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35848947225&partnerID=8YFLogxK
U2 - 10.1089/cap.2007.0058
DO - 10.1089/cap.2007.0058
M3 - Article
VL - 17
SP - 593
EP - 603
JO - Journal of Child and Adolescent Psychopharmacology
JF - Journal of Child and Adolescent Psychopharmacology
SN - 1044-5463
IS - 5
ER -